Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Nausea and Vomiting Induced by Antibody-drug Conjugates (ADCs)

In brief

This study is aimed to evaluate the efficacy and safety of Fosrolapitant and Palonosetron for Antibody-drug conjugate-induced nausea and vomiting

Key facts

Study ID

NCT07692451

Run by

Peking University Cancer Hospital & Institute

People needed

124

Starts

2026-07-15

Expected to finish

2027-09-30

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• 18 years of age or older, of either gender
• Has a diagnosed malignant tumor
• has never been treated with ADCs and is to receive the first course of ADCs
• Predicted life expectancy of ≥ 3 months
• Has a performance status (ECOG scale) of 0 to 1
• Adequate bone marrow, kidney, and liver function
• Women of childbearing potential must have negative pregnancy test (serum test) results within 72 hours prior to enrollment
• Able and willing to provide a written informed consent

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.